Principal Investigator
Overview
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT02142218
Status
Closed for Recruitment
Start/End Dates
Locations
Lions Gate Hospital
Name/Title
Vall Sahraei, Clinical Trials Nurse Coordinator
Phone
Purpose of Study
The primary purpose of this study is to provide treatment with Nivolumab to subjects with histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known BRAF mutation, also progressed on or after treatment with a BRAF inhibitor.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.
Body Locations and Systems
Disorders and Conditions
ClinicalTrials.gov#
NCT02142218
Status
Closed for Recruitment
Start/End Dates
Locations
Lions Gate Hospital
Name/Title
Vall Sahraei, Clinical Trials Nurse Coordinator
Phone
Purpose of Study
The primary purpose of this study is to provide treatment with Nivolumab to subjects with histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have progressed on or after prior treatment with an anti-CTLA4-containing therapy and for subjects with known BRAF mutation, also progressed on or after treatment with a BRAF inhibitor.
Eligibility
Visit ClinicalTrials.gov for more information.
Disclaimer
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.
